MedTrace Logo

Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non Small Cell Lung Cancer (NSCLC) - A Feasibility Study

NCT01836692 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2018-10-31

No results posted yet for this study

Summary

This study is for patients having a course of chest radiotherapy treatment after receiving chemotherapy for the treatment of non-small cell lung cancer. Patients with non-small cell lung cancer have a risk of the tumour in the lung recurring or progressing after treatment.

In this study, we will investigate:

* whether giving a more targeted and individualised type of chest irradiation or radiotherapy to the lung tumour (known as Isotoxic IMRT), is practical and whether it causes side effects which can be tolerated
* whether this new method of delivering the radiotherapy can reduce the risk of the tumour in the lung recurring or progressing
* whether survival can be improved by using this new radiotherapy method

The dose of chest irradiation will be calculated specifically to suit patient's body shape, the position of the lung cancer, and how close healthy tissues are to the tumour. Radiotherapy will be delivered twice a day over a maximum period of 4.5 weeks. The duration of treatment will vary individually according to the delivered dose to the tumour area.

Conditions

  • Non Small Cell Lung Cancer

Interventions

RADIATION

Intensity Modulated Radiotherapy treatment

Intensity Modulated Radiotherapy treatment

Sponsors & Collaborators

  • Cancer Research UK

    collaborator OTHER

  • British Lung Foundation

    collaborator OTHER

  • Sheffield Teaching Hospitals NHS Foundation Trust

    collaborator OTHER

  • Belfast Health and Social Care Trust

    collaborator OTHER

  • The Leeds Teaching Hospitals NHS Trust

    collaborator OTHER

  • Cambridge University Hospitals NHS Foundation Trust

    collaborator OTHER

  • Royal Marsden NHS Foundation Trust

    collaborator OTHER

  • East and North Hertfordshire NHS Trust

    collaborator OTHER_GOV

  • Prof Corinne Faivre-Finn

    lead OTHER

Principal Investigators

  • Corinne Faivre-Finn, MD PhD · The Christie NHS Foundation Trust

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2016-10-31
Completion
2018-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01836692 on ClinicalTrials.gov